UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 160

Sortiert nach

A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm

Clinical infectious diseases, 2022-11, Vol.75 (Suppl 4), p.S490-S497

2022

Link zum Volltext

Verfügbarkeit prüfen

The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases

Clinical infectious diseases, 2022-11, Vol.75 (Suppl 4), p.S502-S509

2022

Link zum Volltext

Verfügbarkeit prüfen

Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations

Journal of antimicrobial chemotherapy, 2019-11, Vol.74 (11), p.3281-3290

2019

Link zum Volltext

Verfügbarkeit prüfen

Prospects for Long-Acting Treatments for Hepatitis C

Clinical infectious diseases, 2022-11, Vol.75 (Suppl 4), p.S525-S529

2022

Link zum Volltext

Verfügbarkeit prüfen

Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs

Journal of antimicrobial chemotherapy, 2018-04, Vol.73 (4), p.1013-1019

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling

Journal of antimicrobial chemotherapy, 2018-01, Vol.73 (1), p.165-172

2018

Link zum Volltext

Verfügbarkeit prüfen

Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?

Journal of antimicrobial chemotherapy, 2021-08, Vol.76 (9), p.2230-2233

2021

Link zum Volltext

Verfügbarkeit prüfen

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide

Journal of antimicrobial chemotherapy, 2019-06, Vol.74 (6), p.1670-1678

2019

Link zum Volltext

Verfügbarkeit prüfen

Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling

The Journal of infectious diseases, 2019-05, Vol.219 (11), p.1735-1742

2019

Link zum Volltext

Verfügbarkeit prüfen

Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy

Clinical infectious diseases, 2012-03, Vol.54 (5), p.724-732

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection

Journal of antimicrobial chemotherapy, 2022-09, Vol.77 (10), p.2706-2712

2022

Link zum Volltext

Verfügbarkeit prüfen

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Journal of antimicrobial chemotherapy, 2021-11, Vol.76 (12), p.3286-3295

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2

Journal of antimicrobial chemotherapy, 2021-07, Vol.76 (8), p.2121-2128

2021

Link zum Volltext

Verfügbarkeit prüfen

Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling

Journal of antimicrobial chemotherapy, 2020-03, Vol.75 (3), p.640-647

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals

Clinical infectious diseases, 2019-01, Vol.68 (3), p.446-452

2019

Link zum Volltext

Verfügbarkeit prüfen

Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment

Clinical infectious diseases, 2022-11, Vol.75 (Suppl 4), p.S510-S516

2022

Link zum Volltext

Verfügbarkeit prüfen

Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research

The Journal of infectious diseases, 2015-06, Vol.211 (suppl 3), p.S115-S125

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

Clinical infectious diseases, 2018-08, Vol.67 (5), p.785-790

2018

Link zum Volltext

Verfügbarkeit prüfen

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake

Journal of antimicrobial chemotherapy, 2016-04, Vol.71 (4), p.1031-1036

2016

Link zum Volltext

Verfügbarkeit prüfen

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19

Journal of antimicrobial chemotherapy, 2021-06, Vol.76 (7), p.1874-1885

2021

Link zum Volltext

Verfügbarkeit prüfen

Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study

Clinical infectious diseases, 2015-08, Vol.61 (3), p.453-463

2015

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study

Clinical infectious diseases, 2009-06, Vol.48 (11), p.e108-e116

2009

Link zum Volltext

Verfügbarkeit prüfen

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics

Journal of antimicrobial chemotherapy, 2020-05, Vol.75 (5), p.1259-1266

2020

Link zum Volltext

Verfügbarkeit prüfen

Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs

Journal of antimicrobial chemotherapy, 2017-03, Vol.72 (3), p.805-811

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 160

Suche als RSS-Feed

Aktive Filter

KollektionOxford Journals 2020 Medicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(160)

Publikationsform

Artikel
(160)

Sprache

Englisch
(160)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm

The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases

Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations

Prospects for Long-Acting Treatments for Hepatitis C

Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs

Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling

Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide

Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling

Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy

Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2

Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling

Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals

Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment

Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19

Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study

Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study

Clinical, pharmacological, and qualitative characterization of drug–drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics

Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs

Aktive Filter

Suchergebnisse filtern